NEW YORK, Dec. 13 — Pharsight and Roche Bioscience will collaborate to link Roche’s genomics discovery program with Pharsight’s software, modeling, and simulation technologies for clinical drug development, the companies said Thursday. The partnership is intended to apply genetic analysis to clinical trials and drug development in order to spur research into individually tailored drugs. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.